JMP Securities analyst Roy Buchanan downgrades iBio (AMEX:IBIO) from Market Outperform to Market Perform.
Lymphoma Therapy Now Approved For Australian Patients With Diffuse Large B-Cell Lymphoma; Minjuvi Provisionally Approved By Therapeutic Goods Administration
Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in adults – diffuse large B-cell lymphoma